Besse, B., Springfeld, C., Baik, C., Hervieu, A., Solomon, B., Moreno, V., Bazhenova, L., Goto, K., Kim, Y., Lu, S., Sun, M., Trone, D., Thamake, S., Cho, B., de Langen, A., Popat, S., Wolf, J., Moro-Sibilot, D., Fang, J., & Drilon, A. (n.d.). update from the ongoing phase 1/2 registrational trial of repotrectinib: results in TKI-naïve and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1). European journal of cancer, 174, S75–S76. http://access.bl.uk/ark:/81055/vdc_100168600366.0x000049